Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 129.46 USD 0.14% Market Closed
Market Cap: 8.4B USD

Wall Street
Price Targets

BPMC Price Targets Summary
Blueprint Medicines Corp

Wall Street analysts forecast BPMC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BPMC is 132.96 USD with a low forecast of 130.29 USD and a high forecast of 141.75 USD.

Lowest
Price Target
130.29 USD
1% Upside
Average
Price Target
132.96 USD
3% Upside
Highest
Price Target
141.75 USD
9% Upside
Blueprint Medicines Corp Competitors:
Price Targets
ARQT
Arcutis Biotherapeutics Inc
37% Upside
MAB
Mabion SA
7% Upside
BCRX
BioCryst Pharmaceuticals Inc
109% Upside
ABBV
Abbvie Inc
6% Upside
ALCLS
Cellectis SA
173% Upside
SPRY
ARS Pharmaceuticals Inc
120% Upside
GRAL
Grail Inc
25% Upside
LEGN
Legend Biotech Corp
114% Upside

Revenue
Forecast

Revenue Estimate
Blueprint Medicines Corp

For the last 8 years the compound annual growth rate for Blueprint Medicines Corp's revenue is 44%. The projected CAGR for the next 3 years is 34%.

44%
Past Growth
34%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Blueprint Medicines Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Net Income
Forecast

Net Income Estimate
Blueprint Medicines Corp

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-13%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BPMC's stock price target?
Price Target
132.96 USD

According to Wall Street analysts, the average 1-year price target for BPMC is 132.96 USD with a low forecast of 130.29 USD and a high forecast of 141.75 USD.

What is Blueprint Medicines Corp's Revenue forecast?
Projected CAGR
34%

For the last 8 years the compound annual growth rate for Blueprint Medicines Corp's revenue is 44%. The projected CAGR for the next 3 years is 34%.

Back to Top